9.22

8.73% +0.74

After Hours: 9.22

CVRx Inc (CVRX)

Overview News Price History Option Chain Financials Why CVRX Down? Discussions Forecast

CVRx Inc stock is currently priced at $9.22, with a 24-hour trading volume of 551.84K. It has seen a +8.73% increased in the last 24 hours and a -46.55% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.00 pivot point. If it approaches the $9.78 resistance level, significant changes may occur.

Previous Close:

$8.48

Open:

$8.72

24h Volume:

551.84K

Market Cap:

$199.11M

Revenue:

$39.30M

Net Income/Loss:

$-41.20M

P/E Ratio:

-4.3905

EPS:

-2.1

Net Cash Flow:

$-39.61M

1W Performance:

-37.24%

1M Performance:

-46.55%

6M Performance:

-47.64%

1Y Performance:

-26.48%

1D Range:

$8.53

$9.49

52W Range:

$7.77

$33.13

CVRx Inc Stock (CVRX) Company Profile

Name

CVRx Inc

Sector

Healthcare (1213)

Industry

Medical Devices (160)

Phone

763 416 2840

Address

9201 West Broadway Avenue, Suite 650, Minneapolis

Employee

Twitter

Next Earnings Date

2024-04-25

Latest SEC Filings

CVRX's Discussions on Twitter

CVRx Inc Stock (CVRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-23	Initiated	Lake Street	Buy
Jul-18-22	Initiated	Craig Hallum	Buy
Jul-26-21	Initiated	Canaccord Genuity	Buy
Jul-26-21	Initiated	Piper Sandler	Overweight
Jul-26-21	Initiated	William Blair	Outperform

CVRx Inc Stock (CVRX) Latest News

CVRx Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire Inc.

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

Zacks Investment Research

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

GlobeNewswire Inc.

CVRx announces availability of additional data supporting long-term benefits of Barostim

GlobeNewswire Inc.

New Strong Buy Stocks for January 30th

Zacks Investment Research

Analyst Expectations For CVRx's Future

Benzinga

CVRx Inc Stock (CVRX) Financials Data

CVRx Inc (CVRX) Revenue 2024

CVRX reported a revenue (TTM) of $39.30 million for the quarter ending December 31, 2023, a +74.89% rise year-over-year.

CVRx Inc (CVRX) Net Income 2024

CVRX net income (TTM) was -$41.20 million for the quarter ending December 31, 2023, a +0.55% increase year-over-year.

CVRx Inc (CVRX) Cash Flow 2024

CVRX recorded a free cash flow (TTM) of -$39.61 million for the quarter ending December 31, 2023, a +8.65% increase year-over-year.

CVRx Inc (CVRX) Earnings per Share 2024

CVRX earnings per share (TTM) was -$1.98 for the quarter ending December 31, 2023, a +1.98% growth year-over-year.

CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.